» Articles » PMID: 25093581

Clinical and Biochemical Function of Polymorphic NR0B1 GGAA-microsatellites in Ewing Sarcoma: a Report from the Children's Oncology Group

Abstract

Background: The genetics involved in Ewing sarcoma susceptibility and prognosis are poorly understood. EWS/FLI and related EWS/ETS chimeras upregulate numerous gene targets via promoter-based GGAA-microsatellite response elements. These microsatellites are highly polymorphic in humans, and preliminary evidence suggests EWS/FLI-mediated gene expression is highly dependent on the number of GGAA motifs within the microsatellite.

Objectives: Here we sought to examine the polymorphic spectrum of a GGAA-microsatellite within the NR0B1 promoter (a critical EWS/FLI target) in primary Ewing sarcoma tumors, and characterize how this polymorphism influences gene expression and clinical outcomes.

Results: A complex, bimodal pattern of EWS/FLI-mediated gene expression was observed across a wide range of GGAA motifs, with maximal expression observed in constructs containing 20-26 GGAA motifs. Relative to white European and African controls, the NR0B1 GGAA-microsatellite in tumor cells demonstrated a strong bias for haplotypes containing 21-25 GGAA motifs suggesting a relationship between microsatellite function and disease susceptibility. This selection bias was not a product of microsatellite instability in tumor samples, nor was there a correlation between NR0B1 GGAA-microsatellite polymorphisms and survival outcomes.

Conclusions: These data suggest that GGAA-microsatellite polymorphisms observed in human populations modulate EWS/FLI-mediated gene expression and may influence disease susceptibility in Ewing sarcoma.

Citing Articles

EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.

Yasir M, Park J, Chun W Int J Mol Sci. 2023; 24(20).

PMID: 37894854 PMC: 10607184. DOI: 10.3390/ijms242015173.


Targeted Therapy for EWS-FLI1 in Ewing Sarcoma.

Gong H, Xue B, Ru J, Pei G, Li Y Cancers (Basel). 2023; 15(16).

PMID: 37627063 PMC: 10452796. DOI: 10.3390/cancers15164035.


Human EWS-FLI protein recapitulates in Drosophila the neomorphic functions that induce Ewing sarcoma tumorigenesis.

Molnar C, Reina J, Herrero A, Heinen J, Mendiz V, Bonnal S PNAS Nexus. 2023; 1(4):pgac222.

PMID: 36714878 PMC: 9802468. DOI: 10.1093/pnasnexus/pgac222.


ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.

Gao Y, He X, Wu X, Huang Y, Toneyan S, Ha T Nat Cell Biol. 2023; 25(2):298-308.

PMID: 36658219 PMC: 10101761. DOI: 10.1038/s41556-022-01060-1.


Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation.

Orth M, Surdez D, Faehling T, Ehlers A, Marchetto A, Grossetete S Cell Rep. 2022; 41(10):111761.

PMID: 36476851 PMC: 10333306. DOI: 10.1016/j.celrep.2022.111761.


References
1.
Bamshad M, Wooding S, Watkins W, Ostler C, Batzer M, Jorde L . Human population genetic structure and inference of group membership. Am J Hum Genet. 2003; 72(3):578-89. PMC: 1180234. DOI: 10.1086/368061. View

2.
Eckert K, Yan G, Hile S . Mutation rate and specificity analysis of tetranucleotide microsatellite DNA alleles in somatic human cells. Mol Carcinog. 2002; 34(3):140-50. DOI: 10.1002/mc.10058. View

3.
May W, Grigoryan R, Keshelava N, Cabral D, Christensen L, Jenabi J . Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One. 2013; 8(12):e80060. PMC: 3846563. DOI: 10.1371/journal.pone.0080060. View

4.
Garcia-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gomez-Lopez G, Pestana A . DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene. 2008; 27(46):6034-43. DOI: 10.1038/onc.2008.203. View

5.
Womer R, West D, Krailo M, Dickman P, Pawel B, Grier H . Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30(33):4148-54. PMC: 3494838. DOI: 10.1200/JCO.2011.41.5703. View